This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by El-Rifai, W.'e. Articles by Miettinen, M. Search for Related Content PubMed PubMed Citation Articles by El-Rifai, W.'e. Articles by Miettinen, M.

DNA Sequence Copy Number Changes in Gastrointestinal Stromal Tumors: Tumor Progression and Prognostic Significance¹

Department of Medical Genetics, Haartman Institute and Helsinki University Central Hospital, University of Helsinki [W. E-R., S. K.], Department of Pathology, Haartman Institute, University of Helsinki [M. S-R., L. C. A.], FIN-00029 HUCH Helsinki, Finland; Department of Soft Tissue Pathology, Armed Forces Institute of Pathology, Washington, DC 20306-6000 [M. M.]; and Department of Human Genetics, National Research Center, Cairo, Egypt [W. E-R.]

	ABSTRACT

Top ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES

 
To identify genetic changes related to tumor progression and find out diagnostic and prognostic genetic markers in gastrointestinal stromal tumors (GISTs), 95 tumor samples (24 benign GISTs, 36 malignant primary GISTs, and 35 GIST-metastases) from 60 patients were studied using comparative genomic hybridization. DNA copy number changes were detected in all samples. Benign GISTs had a mean of 2.6 aberrations/sample (losses:gains, 5:1) and significantly fewer DNA copy number changes and fewer gains than malignant primary and metastatic GISTs (P < 0.01). High-level amplifications were not seen in benign GISTs. Malignant primary GISTs had a mean of 7.5 aberrations/tumor (losses:gains, 1.6:1), whereas the mean number of aberrations/metastatic GIST was 9 (losses:gains, 1.8:1). Frequent changes observed in all GIST groups included losses in chromosome arms 1p (51%), 14q (74%), and 22q (53%). Gains and high-level amplifications at 8q and 17q were significantly more frequent in metastatic GISTs (57 and 43%) than in benign GISTs (8 and 0%; P < 0.001) and malignant primary GISTs (33 and 25%; P < 0.05). Gains and high-level amplifications at 20q were only seen in malignant primary and metastatic GISTs (P < 0.01), and gains at 5p were not detected in benign GISTs (P < 0.01). Losses in chromosome arm 9p were never seen in benign tumors (P < 0.001), and they were more frequent in metastatic GISTs than in malignant primary GISTs (63 and 36%; P < 0.05). Losses in 13q were less frequent in benign GISTs than in malignant primary (P < 0.05) and metastatic (P < 0.01) GISTs. Our results show that several DNA copy number changes are related to the behavior of GISTs and can be used as prognostic markers for tumor progression.

	INTRODUCTION

Top ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES

 
GISTs³ , classified previously as smooth muscle tumors, constitute the most important group of primary mesenchymal tumors of the gastrointestinal tract. These tumors occur at all levels of the gastrointestinal tract and usually present between the sixth and eighth decades. Immunohistochemically, GISTs are usually positive for KIT (CD117) and CD34, variably positive for smooth muscle actin, and usually negative for desmin, in contrast to true smooth muscle tumors. GISTs are negative for S100 protein, in contrast to schwannomas (1, 2) .

Clinically and pathologically, GISTs represent a spectrum of tumors including benign and malignant variants, the latter of which are generally identified by mitotic activity (>1 mitosis/10 high-power field). In some cases, the prediction of biological potential is difficult, because larger tumors with lower mitotic activity may also occasionally metastasize.

CGH enables screening of entire tumor genomes for gains and losses of DNA copy number and consequent mapping of aberrations to chromosomal subregions (reviewed in Refs. 3 and 4 ). Recently, we reported using CGH that loss of genetic material at chromosome arm 14q is the most frequently occurring aberration in both benign and malignant primary GISTs (5) . The DNA copy number changes seen in GISTs were not detected in leiomyomas and leiomyosarcomas (6) . Therefore, the immunophenotypic characteristics and the genetic profile of GISTs have clearly placed it as a separate tumor entity different from other mesenchymal tumors of the gastrointestinal tract. However, the prognostic evaluation of GISTs remained a difficult issue, requiring a complex multiparametric approach.

This study was performed to analyze the CGH changes in benign and malignant primary GISTs and to investigate whether progressive DNA copy number changes occur in recurrent and metastatic GISTs. We also investigated whether any DNA copy number change has prognostic significance for GISTs.

	MATERIALS AND METHODS

Top ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES

 
Tumors.
Ninety-five GIST samples from 60 patients were included in the study. The samples consisted of 24 benign GISTs, 36 malignant primary GISTs, and 35 GIST metastases that were available from 15 of the malignant primary GISTs. Immunohistochemically identified leiomyomas and leiomyosarcomas (desmin-positive, CD117-negative) and schwannomas (S100-protein positive, CD117-negative) were excluded from the study. Most GISTs were CD117 and CD34 positive (92 and 72%, respectively). The categorization of GISTs into benign and malignant tumors was based on mitotic counts. Benign GISTs had <2 mitoses/10 high-power field. Malignant or potentially malignant GISTs had >1 mitosis/10 high-power fields. Follow-up data for 6–209 months (mean, 41 months) were available for all patients except four (nos. 25, 26, 29, and 48). None of the patients with benign tumors showed recurrence or metastases.

CGH.
Because CGH sensitivity requires at least 50% of tumor material within a sample, paraffin-embedded tissue sections were dissected to obtain at least 70% of tumor cells. DNA from paraffin-embedded tissue sections was extracted as described earlier (7) .

CGH was performed according to standard procedures with a modification using a mixture of fluorochromes conjugated to dCTP and dUTP nucleotides for nick translation (8) . Hybridizations, washings, and ISIS digital image analysis (Metasystems GmbH, Altlussheim, Germany) were performed as described elsewhere (5) .

Controls.
In each CGH experiment, a negative control (peripheral blood DNA from a healthy donor) and a positive control were included. The positive control was a gastric tumor with known DNA copy number changes. On the basis of our earlier reports and the control results, we used 1.17 and 0.85 as cutoff levels for gains and losses, respectively. All of the CGH results were confirmed using a 99% confidence interval.

Statistical Analysis.
All of the CGH results were confirmed using a 99% confidence interval. Briefly, intra-experiment SDs for all positions in the CGH ratio profiles were calculated from the variation of the ratio values of all homologous chromosomes within the experiment. Confidence intervals for the ratio profiles were then computed by combining them with an empirical inter-experiment SD and by estimating error probabilities based on the t distribution. For the analysis of the frequencies of DNA copy number changes in primary and metastatic GISTs, we used Fisher’s exact two-tailed test. Ps <0.05 were considered significant.

	RESULTS

Top ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES

 
Changes in DNA copy numbers were detected in all samples. DNA copy number changes were seen in all chromosomes in malignant primary and metastatic GISTs, whereas fewer chromosomes were involved in benign GISTs (Figs. 1 and 2 ). Benign GISTs had a mean of 2.6 aberrations/case (losses:gains, 5:1) and contained significantly fewer DNA copy number changes and fewer gains than malignant primary and metastatic GISTs (P < 0.01). High-level amplifications were not seen in benign GISTs. In malignant primary GISTs, the mean number of aberrations/case was 7.5 (losses:gains, 1.6:1), whereas the mean was 9 in metastatic GISTs (losses:gains, 1.8:1). The CGH profiles in metastatic GISTs and malignant primary tumors were similar, but metastatic GISTs showed a larger number of high-level amplifications. There was no correlation between the location and any specific DNA copy number changes.

View larger version (27K): [in this window] [in a new window] [Download PPT slide]   Fig. 1. Summary of DNA copy number gains and losses detected by CGH in 60 GIST patients. Each bar represents one patient, regardless of the number of samples available, and the minimal common overlapping regions are presented. Gains are on the right hand side, losses on the left. Green broken lines, benign tumors; green continuous lines, malignant primary tumors that had no metastases samples. Blue lines, the aberration was seen in the malignant primary tumor and in at least one metastatic sample from the same patient. Red lines, changes that were seen on metastatic samples but not in their primary tumors for the same patient.

View larger version (28K): [in this window] [in a new window] [Download PPT slide]   Fig. 2. Comparative frequencies of losses (left) and gains (right) detected in 24 benign GISTs (green), 36 malignant primary GISTs (blue), and 35 metastatic GISTs (red). Chromosomal numbers are shown in the middle, and the minimal common overlapping regions, when applicable, are added to each bar.

Gains and high-level amplifications at 8q and 17q were significantly more often detected in metastatic GISTs (57 and 43%) than in benign GISTs (8 and 0%; P < 0.001) and malignant primary GISTs (33 and 25%; P < 0.05). Gains and high-level amplifications at 20q were only seen in malignant primary and metastatic GISTs (P < 0.01), and gains at 5p were not detected in benign GISTs (P < 0.01). Losses in 9p were never seen in benign tumors (P < 0.001), and they were more frequent in metastatic GISTs than in malignant primary tumors (63 and 36%; P < 0.05). The losses in 13q were less frequent in benign GISTs than in malignant primary (P < 0.05) and metastatic (P < 0.01) GISTs. In addition, several other changes were seen more frequently in malignant primary and metastatic GISTs than in benign GISTs. The details of DNA copy number changes are shown in Table 1 and Fig. 1 . Fig. 2 shows the relative frequencies of the aberrations in all GISTs, and Table 2 summarizes the significant DNA copy number changes.

	DISCUSSION

Top ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES

Gains and high-level amplifications at 5p, 8q, 17q, and 20q and losses in 9p, 13q, 15q, and 19q correlated with malignant primary GISTs and metastatic GISTs. Moreover, the gains at 8q, 17q, and 20q and the losses in 9p were more frequent in metastatic GISTs than in malignant primary GISTs (P < 0.05). Therefore, clones with this genetic make-up have a potential capability of developing metastases.

Losses in 1p, 14q, and 22q seen in benign GISTs seem to be unique because they have been reported rarely in other tumors at frequencies as high as observed in GISTs (9) . These changes were frequently seen in benign GISTs, indicating that they may be early events in GIST development. The fact that these losses were maintained with tumor progression suggests that they are required for the maintenance of GIST phenotype. The present extended study also supports the notion that these changes may be unique for GIST development. Recently, we reported high-resolution deletion mapping of chromosome 14 in GISTs and identified two possible tumor suppressor loci in 14q11.2 and 14q23 (10) .

The gains/high-level amplifications at 5p, 8q, 17q, and 20q as well as the losses in 9p, 13q, 15q, and 19q were detected in many malignant GISTs and their metastases. Such changes have also been reported in several other tumors, such as carcinomas of lung, breast, and ovary, and in squamous cell carcinomas of the head with variable frequencies (reviewed in Refs. 3 and 4 ). Gains and high-level amplifications at 8q22–q24 and 17q21–qter have been implicated as poor prognostic indicators in breast cancer, ovarian cancer, osteosarcomas, and neuroblastomas (11–14) . The gains and high-level amplifications at 8q and 20q correlate with invasiveness in breast cancer (15, 16) .

Although these chromosomal regions are known to contain several oncogenes, such as CMYC at 8q and ERBB2 at 17q, the possibility of yet undiscovered oncogenes cannot be ruled out (14) . At 20q, several genes have been implicated in breast cancer, and the region is known to harbor specific amplified genes (AIB1, AIB3, and AIB4; Ref. 17 ). Several candidate genes are located at 20q, e.g., the PTP1B/PTPN1 gene (20q12), which is involved in growth regulation, and the MYBL2 gene (20q13), which plays an important role in cell cycle progression. Moreover, the human cellular apoptosis susceptibility (CAS) gene has been mapped to this same region (18) . There are no known oncogenes that map to 5p.

Losses in 9p were associated with recurrences and unfavorable outcome in squamous cell carcinoma of the head and neck (19) and in astrocytic tumors (20) . Losses in 13q12–q13 are associated with poor prognosis in familial and sporadic breast cancer (21) . Losses in 15q have been observed rarely upon CGH. LOH studies have suggested the presence of a putative tumor suppressor gene in 15q in small cell lung cancer (22) . However, there are no data related to its potential prognostic significance or identified tumor suppressor genes.

In summary, our results show that genetic changes can be used as a complementary diagnostic tool for the prognostication of GISTs and for the differentiation between benign and malignant tumors. The increased number of changes and/or increased number of gains correlate with malignant behavior. Furthermore, the genetic changes seen as gains at 5p, 8q, 17q, and 20q and losses in 9p, 13q, 15q, and 19q are new prognostic parameters for GISTs.

	FOOTNOTES

¹ Supported by grants from the Finnish Cancer Society and the University of Helsinki in Finland.

² To whom requests for reprints should be addressed, at Department of Medical Genetics, Helsinki University Central Hospital, P. O. Box 404 (Haartmanink. 3, 4th floor), FIN-00029 HUCH, Helsinki, Finland. Phone: 358-9-1912-6527; Fax: 358-9-1912-6788; E-mail: Sakari.Knuutila{at}Helsinki.FI

³ The abbreviations used are: GIST, gastrointestinal stromal tumor; CGH, comparative genomic hybridization.

Received 12/30/99. Accepted 5/17/00.

	REFERENCES

Top ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES

 

1. Sarlomo-Rikala M., Kovatich A., Barusevicius A., Miettinen M. CD117: a sensitive marker for gastrointestinal stromal tumors that is more specific than CD34. Mod. Pathol, 11: 728-734, 1998.[Medline]
2. Miettinen M., Sarlomo-Rikala M., Lasota J. Gastrointestinal stromal tumors: recent advances in understanding of their biology. Hum. Pathol, 30: 1213-1220, 1999.[Medline]
3. Knuutila S., Björkqvist A-M., Autio K., Tarkkanen M., Wolf M., Monni O., Szymanska J., Larramendy M. L., Tapper J., Pere H., El-Rifai W., Hemmer S., Wasenius V-M., Vidgren V., Zhu Y. DNA copy number amplifications in human neoplasms. Review of comparative genomic hybridization studies. Am. J. Pathol, 152: 1107-1123, 1998.[Abstract]
4. Knuutila S., Aalto Y., Autio K., Björkqvist A-M., El-Rifai W., Hemmer S., Huhta T., Kettunen E., Kiuru-Kuhlefelt S., Larramendy M. L., Lushnikova T., Monni O., Pere H., Tapper J., Tarkkanen M., Varis A., Wasenius V-M., Wolf M., Zhu Y. DNA copy number losses in human neoplasms. Am. J. Pathol, 155: 683-694, 1999.[Abstract/Free Full Text]
5. El-Rifai W., Sarlomo-Rikala M., Miettinen M., Knuutila S., Andersson L. C. DNA copy number losses in chromosome 14: an early change in gastrointestinal stromal tumors. Cancer Res, 56: 3230-3233, 1996.[Abstract/Free Full Text]
6. El-Rifai W., Sarlomo-Rikala M., Knuutila S., Miettinen M. DNA copy number changes in development and progression in leiomyosarcoma of soft tissues. Am. J. Pathol, 153: 985-990, 1998.[Abstract/Free Full Text]
7. Miller S. A., Dykes D. D., Polesky H. F. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res, 16: 1215 1988.[Free Full Text]
8. El-Rifai W., Larramendy M. L., Björkqvist A-M., Hemmer S., Knuutila S. Optimization of comparative genomic hybridization using fluorochrome conjugated to dCTP and dUTP nucleotides. Lab. Investig, 77: 699-700, 1997.[Medline]
9. Mitelman, F. Catalog of Chromosome Aberrations in Cancer, Ed. 4, 1987. New York: Wiley-Liss, Inc., 1991.
10. El-Rifai W., Sarlomo-Rikala M., Miettinen M., Andersson L. C., Knuutila S. High-resolution deletion mapping of chromosome 14 in stromal tumors of the gastrointestinal tract suggests two distinct tumor suppressor loci. Genes Chromosomes Cancer, 27: 387-391, 2000.[Medline]
11. Bown N., Cotterill S., Lastowska M., O’Neill S., Pearson A. D., Plantaz D., Meddeb M., Danglot G., Brinkschmidt C., Christiansen H., Laureys G., Speleman F. Gain of chromosome arm 17q and adverse outcome in patients with neuroblastoma. N. Engl. J. Med, 340: 1954-1961, 1999.[Abstract/Free Full Text]
12. Tarkkanen M., Elomaa I., Blomqvist C., Kivioja A. H., Kellokumpu-Lehtinen P., Bohling T., Valle J., Knuutila S. DNA sequence copy number increase at 8q: a potential new prognostic marker in high-grade osteosarcoma. Int. J. Cancer, 84: 114-121, 1999.[Medline]
13. Arnold N., Hagele L., Walz L., Schempp W., Pfisterer J., Bauknecht T., Kiechle M. Overrepresentation of 3q and 8q material and loss of 18q material are recurrent findings in advanced human ovarian cancer. Genes Chromosomes Cancer, 16: 46-54, 1996.[Medline]
14. Bärlund M., Tirkkonen M., Forozan F., Tanner M. M., Kallioniemi O., Kallioniemi A. Increased copy number at 17q22–q24 by CGH in breast cancer is due to high-level amplification of two separate regions. Genes Chromosomes Cancer, 20: 372-376, 1997.[Medline]
15. Tanner M. M., Tirkkonen M., Kallioniemi A., Holli K., Collins C., Kowbel D., Gray J. W., Kallioniemi O. P., Isola J. Amplification of chromosomal region 20q13 in invasive breast cancer: prognostic implications. Clin. Cancer Res, 1: 1455-1461, 1995.[Abstract]
16. Isola J. J., Kallioniemi O. P., Chu L. W., Fuqua S. A., Hilsenbeck S. G., Osborne C. K., Waldman F. M. Genetic aberrations detected by comparative genomic hybridization predict outcome in node-negative breast cancer. Am. J. Pathol, 147: 905-911, 1995.[Abstract]
17. Tanner M. M., Tirkkonen M., Kallioniemi A., Isola J., Kuukasjärvi T., Collins C., Kowbel D., Guan X. Y., Trent J., Gray J. W., Meltzer P., Kallioniemi O. P. Independent amplification and frequent co-amplification of three nonsyntenic regions on the long arm of chromosome 20 in human breast cancer. Cancer Res, 56: 3441-3445, 1996.[Abstract/Free Full Text]
18. Brinkmann U., Gallo M., Polymeropoulos M. H., Pastan I. The human CAS (cellular apoptosis susceptibility) gene mapping on chromosome 20q13 is amplified in BT474 breast cancer cells and part of aberrant chromosomes in breast and colon cancer cell lines. Genome Res, 6: 187-194, 1996.[Abstract/Free Full Text]
19. Lydiatt W. M., Davidson B. J., Schantz S. P., Caruana S., Chaganti R. S. 9p21 deletion correlates with recurrence in head and neck cancer. Head Neck, 20: 113-118, 1998.[Medline]
20. Maruno M., Yoshimine T., Muhammad A. K., Tokiyoshi K., Hayakawa T. Loss of heterozygosity of microsatellite loci on chromosome 9p in astrocytic tumors and its prognostic implications. J. Neuro-Oncol, 30: 19-24, 1996.[Medline]
21. Eiriksdottir G., Johannesdottir G., Ingvarsson S., Bjornsdottir I. B., Jonasson J. G., Agnarsson B. A., Hallgrimsson J., Gudmundsson J., Egilsson V., Sigurdsson H., Barkardottir R. B. Mapping loss of heterozygosity at chromosome 13q: loss at 13q12–q13 is associated with breast tumour progression and poor prognosis. Eur. J. Cancer, 34: 2076-2081, 1998.
22. Stanton S. E., Shin S. W., Johnson B. E., Meyerson M. Recurrent allelic deletions of chromosome arms 15q and 16q in human small cell lung carcinomas. Genes Chromosomes Cancer, 27: 323-331, 2000.[Medline]

This article has been cited by other articles:

				H.-Y. Huang, S.-H. Li, S.-C. Yu, F.-F. Chou, C.-C. Tzeng, T.-H. Hu, Y.-H. Uen, Y.-F. Tian, Y.-H. Wang, F.-M. Fang, et al. Homozygous Deletion of MTAP Gene as a Poor Prognosticator in Gastrointestinal Stromal Tumors Clin. Cancer Res., November 15, 2009; 15(22): 6963 - 6972. [Abstract] [Full Text] [PDF]

				L. Rink, Y. Skorobogatko, A. V. Kossenkov, M. G. Belinsky, T. Pajak, M. C. Heinrich, C. D. Blanke, M. von Mehren, M. F. Ochs, B. Eisenberg, et al. Gene expression signatures and response to imatinib mesylate in gastrointestinal stromal tumor Mol. Cancer Ther., August 1, 2009; 8(8): 2172 - 2182. [Abstract] [Full Text] [PDF]

				C. Tarn, L. Rink, E. Merkel, D. Flieder, H. Pathak, D. Koumbi, J. R. Testa, B. Eisenberg, M. von Mehren, and A. K. Godwin Insulin-like growth factor 1 receptor is a potential therapeutic target for gastrointestinal stromal tumors PNAS, June 17, 2008; 105(24): 8387 - 8392. [Abstract] [Full Text] [PDF]

				Y. Suehara, T. Kondo, K. Seki, T. Shibata, K. Fujii, M. Gotoh, T. Hasegawa, Y. Shimada, M. Sasako, T. Shimoda, et al. Pfetin as a Prognostic Biomarker of Gastrointestinal Stromal Tumors Revealed by Proteomics Clin. Cancer Res., March 15, 2008; 14(6): 1707 - 1717. [Abstract] [Full Text] [PDF]

				K. A. Janeway, B. Liegl, A. Harlow, C. Le, A. Perez-Atayde, H. Kozakewich, C. L. Corless, M. C. Heinrich, and J. A. Fletcher Pediatric KIT Wild-Type and Platelet-Derived Growth Factor Receptor {alpha} Wild-Type Gastrointestinal Stromal Tumors Share KIT Activation but not Mechanisms of Genetic Progression with Adult Gastrointestinal Stromal Tumors Cancer Res., October 1, 2007; 67(19): 9084 - 9088. [Abstract] [Full Text] [PDF]

				L. A. Meza-Zepeda, S. H. Kresse, A. H. Barragan-Polania, B. Bjerkehagen, H. O. Ohnstad, H. M. Namlos, J. Wang, B. E. Kristiansen, and O. Myklebost Array Comparative Genomic Hybridization Reveals Distinct DNA Copy Number Differences between Gastrointestinal Stromal Tumors and Leiomyosarcomas. Cancer Res., September 15, 2006; 66(18): 8984 - 8993. [Abstract] [Full Text] [PDF]

				L Tornillo and L M Terracciano An update on molecular genetics of gastrointestinal stromal tumours. J. Clin. Pathol., June 1, 2006; 59(6): 557 - 563. [Abstract] [Full Text] [PDF]

				O. Maertens, H. Prenen, M. Debiec-Rychter, A. Wozniak, R. Sciot, P. Pauwels, I. De Wever, J. R. Vermeesch, T. de Raedt, A. De Paepe, et al. Molecular pathogenesis of multiple gastrointestinal stromal tumors in NF1 patients Hum. Mol. Genet., March 15, 2006; 15(6): 1015 - 1023. [Abstract] [Full Text] [PDF]

				R Penzel, S Aulmann, M Moock, M Schwarzbach, R J Rieker, and G Mechtersheimer The location of KIT and PDGFRA gene mutations in gastrointestinal stromal tumours is site and phenotype associated J. Clin. Pathol., June 1, 2005; 58(6): 634 - 639. [Abstract] [Full Text] [PDF]

				R. Schneider-Stock, C. Boltze, J. Lasota, B. Peters, C. L. Corless, P. Ruemmele, L. Terracciano, M. Pross, L. Insabato, D. Di Vizio, et al. Loss of p16 Protein Defines High-Risk Patients with Gastrointestinal Stromal Tumors: A Tissue Microarray Study Clin. Cancer Res., January 15, 2005; 11(2): 638 - 645. [Abstract] [Full Text] [PDF]

				C. L. Corless, J. A. Fletcher, and M. C. Heinrich Biology of Gastrointestinal Stromal Tumors J. Clin. Oncol., September 15, 2004; 22(18): 3813 - 3825. [Abstract] [Full Text] [PDF]

				N Koon, R Schneider-Stock, M Sarlomo-Rikala, J Lasota, M Smolkin, G Petroni, A Zaika, C Boltze, F Meyer, L Andersson, et al. Molecular targets for tumour progression in gastrointestinal stromal tumours Gut, February 1, 2004; 53(2): 235 - 240. [Abstract] [Full Text] [PDF]

				G. Sommer, V. Agosti, I. Ehlers, F. Rossi, S. Corbacioglu, J. Farkas, M. Moore, K. Manova, C. R. Antonescu, and P. Besmer Gastrointestinal stromal tumors in a mouse model by targeted mutation of the Kit receptor tyrosine kinase PNAS, May 27, 2003; 100(11): 6706 - 6711. [Abstract] [Full Text] [PDF]

				R. Schneider-Stock, C. Boltze, J. Lasota, M. Miettinen, B. Peters, M. Pross, A. Roessner, and T. Gunther High Prognostic Value of p16INK4 Alterations in Gastrointestinal Stromal Tumors J. Clin. Oncol., May 1, 2003; 21(9): 1688 - 1697. [Abstract] [Full Text] [PDF]

				S. Singer, B. P. Rubin, M. L. Lux, C.-J. Chen, G. D. Demetri, C. D.M. Fletcher, and J. A. Fletcher Prognostic Value of KIT Mutation Type, Mitotic Activity, and Histologic Subtype in Gastrointestinal Stromal Tumors J. Clin. Oncol., September 15, 2002; 20(18): 3898 - 3905. [Abstract] [Full Text] [PDF]

				J. Andersson, H. Sjogren, J. M. Meis-Kindblom, G. Stenman, P. Aman, and L.-G. Kindblom The Complexity of KIT Gene Mutations and Chromosome Rearrangements and Their Clinical Correlation in Gastrointestinal Stromal (Pacemaker Cell) Tumors Am. J. Pathol., January 1, 2002; 160(1): 15 - 22. [Abstract] [Full Text] [PDF]

				S. V. Allander, N. N. Nupponen, M. Ringner, G. Hostetter, G. W. Maher, N. Goldberger, Y. Chen, J. Carpten, A. G. Elkahloun, and P. S. Meltzer Gastrointestinal Stromal Tumors with KIT Mutations Exhibit a Remarkably Homogeneous Gene Expression Profile Cancer Res., December 1, 2001; 61(24): 8624 - 8628. [Abstract] [Full Text] [PDF]

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by El-Rifai, W.'e. Articles by Miettinen, M. Search for Related Content PubMed PubMed Citation Articles by El-Rifai, W.'e. Articles by Miettinen, M.